Skip to main content
رجوع
AGIO logo

Agios Pharmaceuticals, Inc.

جودة البيانات: 100%
AGIO
NASDAQ Healthcare Biotechnology
KWD 28.35
▲ KWD 0.24 (0.85%)
القيمة السوقية: 1.66B
نطاق اليوم
KWD 27.46 KWD 28.65
نطاق 52 أسبوعًا
KWD 22.24 KWD 46.00
حجم التداول
750,001
متوسط 50 يوم / 200 يوم
KWD 28.20 / KWD 33.93
الإغلاق السابق
KWD 28.11

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E -4.0 0.4
P/B 1.4 2.9
ROE % -30.2 3.9
Net Margin % -764.0 3.8
Rev Growth 5Y % 10.0
D/E 0.1 0.2

السعر المستهدف للمحللين

Hold
KWD 41.500 +46.4%
Low: KWD 25.000 High: KWD 62.000
ربحية السهم المستقبلية
-KWD 6.632
الإيرادات المقدّرة
91 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 -KWD 0.064
-KWD 0.091 – -KWD 0.037
670 M 6
FY2029 -KWD 2.350
-KWD 3.328 – -KWD 1.355
500 M 6
FY2028 -KWD 3.423
-KWD 5.010 – -KWD 1.097
370 M 8

النقاط الرئيسية

Earnings declined -161.27% over the past year
Debt/Equity of 0.05 — conservative balance sheet
Negative free cash flow of -377.29M
PEG of 0.02 suggests growth is underpriced
Capital efficient — spends only 7.99% of revenue on capex

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)48.03%
Earnings (1Y)-161.27%
FCF Growth (3Y)N/A

الجودة

Return on Equity
-30.20%
ROIC-28.21%
Net Margin-764.01%
Op. Margin-873.87%

الأمان

Debt / Equity
0.05
Current Ratio11.46
Interest Coverage0.00

التقييم

P/E Ratio
-4.02
P/B Ratio1.39
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 48.03% Revenue Growth (3Y) 41.92%
Earnings Growth (1Y) -161.27% Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 54.03M Net Income (TTM) -412.78M
ROE -30.20% ROA -31.82%
Gross Margin 88.26% Operating Margin -873.87%
Net Margin -764.01% Free Cash Flow (TTM) -377.29M
ROIC -28.21% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.05 Current Ratio 11.46
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -4.02 P/B Ratio 1.39
P/S Ratio 30.74 PEG Ratio 0.02
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 1.66B Enterprise Value 1.63B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 54.03M 36.50M 26.82M 14.24M 0.0
Net Income -412.78M 673.73M -352.09M -231.80M 1.60B
EPS (Diluted) -7.12 11.64 -6.33 -4.23 -6.36
Gross Profit 47.68M 32.33M 17.32M 12.54M -18.78M
Operating Income -472.13M -425.74M -391.49M -389.05M -378.42M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.30B 1.66B 937.12M 1.24B 1.44B
Total Liabilities 104.11M 122.24M 126.10M 137.90M 145.76M
Shareholders' Equity 1.19B 1.54B 811.02M 1.10B 1.29B
Total Debt 62.02M 56.99M 72.00M 85.66M 97.09M
Cash & Equivalents 89.13M 76.25M 88.21M 139.26M 203.13M
Current Assets 942.05M 965.60M 833.84M 832.77M 1.06B
Current Liabilities 82.21M 81.16M 67.96M 62.63M 59.83M